Parion Sciences Announces Upcoming Presentations of Data at the North American Cystic Fibrosis Conference Being Held October 8 through 10, 2015

  • Data From Preclinical and Clinical Research on P-1037(VX-371) to be Presented
  • Additional Data Presentation Includes a Review of a Novel in Silico Approach Towards Identification of CFTR Correctors

DURHAM, N.C., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that 3 abstracts from its pulmonary research and development efforts will be presented at the 29th Annual North American Cystic Fibrosis Conference (NACFC) in Phoenix Arizona, October 8 through 10, 2015. Data to be presented on P-1037 (also known as VX-371) includes preclinical models as well as a review of the clinical data. A review of a novel in silico model to identify new CFTR correctors will also be presented. The accepted abstracts and related presentations are listed below:

P-1037 Presentations at NACFC

  • “The ENaC Inhibitor P-1037 is a CFTR-Independent Therapeutic Agent that Promotes Sustained Airways Hydration and Mucociliary Transport.” Poster 201. This data will also be presented in workshop session II (workshop 14) on Friday October 9th at 3:10 p.m.
  • “Safety and Disposition of the Novel ENaC Blocker P-1037 in CF Patients, Compared to Healthy Subjects.” Poster 217. This data will also be presented in workshop session III (workshop 24) on Saturday October 10th at 10:30 a.m.

P-1037/VX-371 is being developed in collaboration with Vertex Pharmaceuticals based on an agreement announced in June 2015. The Phase 2 CLEAN-CF clinical study of P-1037/VX-371 is currently enrolling people with Cystic Fibrosis 12 years of age and above. The initiation of the Phase 2 clinical trials was supported by an award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation. For additional information on the CLEAN-CF clinical trial, please go to the website link:

CFTR Corrector Presentation at NACFC

  • “A Validated Novel Dynamic In Silico Approach Towards the Identification of CFTR Correctors.” Poster 40.

About ENaC Inhibitors and P-1037

Epithelial sodium channel (ENaC) inhibitors are designed to block the sodium channels on the airway surfaces. In pulmonary diseases where there is a build-up of excessively concentrated mucus, such as cystic fibrosis and chronic obstructive pulmonary disease, preclinical models have demonstrated that blocking the ENaC channel promotes fluid secretion and re-hydrates the mucus layers. Hydration of mucosal surfaces may restore airway clearance, potentially reducing infection and improving lung function.

About CFTR Correctors

CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most prevalent disease-causing mutation in CFTR, F508del, causes the CFTR protein to be mis-folded, ultimately resulting in the loss of CFTR function, dehydration of the mucus membranes, and impairment of pulmonary, GI, and pancreatic function.

Parion is developing a novel series of small molecule CFTR correctors targeted at restoring the proper folding and stability to the F508del CFTR protein. The Parion CFTR correctors are being developed as oral agents intended to improve CFTR function in all organs affected by CF.

About Parion Sciences

Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation Therapeutics, Inc. For more information, please see our website at

Contact: Paul Boucher President & CEO, Parion Sciences 919-313-1195

Source: Parion Sciences